Clinical Proof of concept for a RNA-targeting Oligonucleotide for a Cystic fibrosis-F508del MEDication

Project Information

PRO-CF-MED

Grant agreement ID: 633545

DOI 10.3030/633545

Project closed

EC signature date 21 April 2015

Start date 1 May 2015

End date 31 December 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 21 237 179,50

EU contribution € 5 997 139,00

Coordinated by

PROQR THERAPEUTICS NV
Netherlands

Deliverables

Websites, patent fillings, videos etc. (1)

PRO-CF-MED project website developed including project updates and patient ‘friendly’ section

Publications

Other (1)

QR-010 significantly improves CFTR function in nasal potential difference proof of concept study in subjects with CF homozygous for the F508del-CFTR mutation

Author(s): I Sermet-Gaudelus, D Nichols, JA Nick, C De Boeck, JP Clancy, GM Solomon, SM Rowe, JS Elborn, MA MAll, JA Bolognese, F Bouisset, W den Hollander, N Lamontagne, N Tomkinson, N Henig
Published in: 2016
Publisher: poster at the North American Cystic Fibrosis Conference

Peer reviewed articles (1)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

Author(s): Sabrina Noel, Bela Z Schmidt, Jeremy Haaf, Teresinha Leal
Published in: Clinical Pharmacology: Advances and Applications, Issue Volume 8, 2016, Page(s) 127-140, ISSN 1179-1438
Publisher: Dove Medical Press Ltd
DOI: 10.2147/CPAA.S100759

Intellectual Property Rights

Patent (1)

OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL

Application/Publication number: EP 13760133
Date: 2013-07-12
Applicant(s): PROQR THERAPEUTICS NV